Evangelos Kiskinis | Director Stem Cell Core Facility Co-Director, Stem Cell and Regenerative Biology
Northwestern University

Evangelos Kiskinis, Director Stem Cell Core Facility Co-Director, Stem Cell and Regenerative Biology, Northwestern University

Dr. Kiskinis earned a degree in Molecular Biology from the University of Surrey and a Masters and PhD from Imperial College in the United Kingdom. Dr. Kiskinis carried out postdoctoral research training in the Lab of Professor Kevin Eggan at the Department of Stem Cell and Regenerative Biology at Harvard University. While at Harvard, Evangelos acquired expertise in human stem cell biology and explored the possibility of using patient-specific stem cells to investigate neurodegenerative diseases with a particular focus on Amyotrophic Lateral Sclerosis (ALS). His research efforts lead to the discovery of molecular pathways that become dysfunctional in ALS patients as well as to the discovery of a small molecule therapeutic that is currently being tested in a clinical trial for ALS patients.

In January 2015, Evangelos was appointed as an Assistant Professor of Neurology and Physiology at the Feinberg School of Medicine, Northwestern University. Dr. Kiskinis’ lab uses human stem cells to develop novel models for neurological diseases including ALS and ion-channel forms of epileptic syndromes such as Dravet Syndrome. He has been the recipient of prestigious fellowships from the European Molecular Biology Organization as well as from the New York Stem Cell Foundation and the Charles A. King Trust Medical Foundation. At Northwestern University, Dr. Kiskinis also serves as the Scientific Director of the Stem Cell Core Facility, and as the Co-Director of the Stem Cell and Regenerative Biology Initiative.

Appearances:



Precision 2018 Day 3 @ 12:00

Probing disease mechanisms in ion-channel epilepsy using iPSCs, reprogramming and optogenetic approaches to provide personalized therapeutic approaches

  • The lack of easy accessibility to the cells of the nervous system has hampered progress towards the discovery of degenerative mechanisms as well as more effective treatments for neurological diseases
  • The ground-breaking technology of reprogramming, which allows for the generation of patient specific induced pluripotent stem cells (iPSCs) has created an unprecedented opportunity for a new approach towards developing cellular models of human disease
  • We employ this approach to generate cortical excitatory and inhibitory neurons as well as spinal motor neurons and astrocytes from individual patients
  • We use gene-editing techniques to introduce or fix mutations and then study the neurons we make by classical methods including immunocytochemistry, biochemistry, global genomic analysis, live cell imaging as well as by non-invasive electrophysiological recording techniques

back to speakers